Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Ltd. reports encouraging early results in its Phase 2a ACCENT trial for advanced pancreatic cancer, with three patients showing confirmed partial responses to the treatment combining narmafotinib and standard chemotherapy. The company has reached half of its initial efficacy threshold and anticipates further recruitment for the full trial cohort. The trial’s success hinges on the effectiveness of narmafotinib, a potent inhibitor targeting a protein commonly overexpressed in various cancers.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
